News
Videos
Conferences
Events
Resources
Subscribe

|Videos|June 22, 2022

Tivozanib: Adverse Event Profile and How Toxicities are Managed

Author(s)Thomas Hutson, DO, PharmD

Dr Thomas Hutson reviews the adverse event profile of tivozanib and provides advice to community oncologists on how to best manage these toxicities.

Episodes in this series

EP. 1 Treatment Options for Patients with Renal Cell Carcinoma (RCC)

EP. 1 Treatment Options for Patients with Renal Cell Carcinoma (RCC)

EP. 2 Clinical Implications of the TIVO-3 Trial

EP. 2 Clinical Implications of the TIVO-3 Trial

EP. 3 Tivozanib: Adverse Event Profile and How Toxicities are Managed

EP. 4 Experience with Tivozanib in the 3rd Line Setting for Patients with RCC

EP. 4 Experience with Tivozanib in the 3rd Line Setting for Patients with RCC

EP. 5 Future Perspectives in Renal Cell Carcinoma (RCC)

EP. 5 Future Perspectives in Renal Cell Carcinoma (RCC)

Newsletter

Stay up to date on cancer updates, research and education

Related Content

The Future of CLL Care: Medical Breakthroughs and Patient-Physician Collaboration

September 20th 2024

Living Well With CLL: Nutrition, Exercise, and Lifestyle Tips From Patients and Doctors

September 20th 2024

Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs

September 13th 2024

CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making

September 13th 2024

LL Treatment Roadmap: Navigating First-Line Options With Your Doctor

September 6th 2024

Trending on CURE

FDA Approves Imfinzi Plus Chemo in GC/GEJC

How New Therapies Are Changing the Game for Small Cell Lung Cancer

How Vaccines Can Partner With Immunotherapy to Treat Lung Cancer

A Cancer Survivor's Thanksgiving Reflection

AVZO-103 Wins FDA Designation for Previously Treated Urothelial Cancer

© 2025 MJH Life Sciences^®

All rights reserved.